Skip to main content
Equibles

ACB · Aurora Cannabis Inc · Documents

Use ACB with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ACB.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
7.4000 CAD +0.1100 (+1.51%) At close · Nov 6 Intraday price with Plus
Rebalance outlook locked

The company's reports, filings, earnings calls and investor events, most recent first. Search these from Claude or ChatGPT →

Annual report FY2026 Revenue 320.59M CAD up 11.0% 40-F filed Jun 11, 2026 Earnings call Q2 2026 earnings call Held Sep 30, 2025
2026
Nov 5
Report SEDAR+
MD&A
Nov 4
Current report 6-K
Organigram agrees to acquire cannabis company for C$7.80 per share

Organigram Global Inc. agreed to acquire Aurora Cannabis Inc. for C$7.80 in total consideration per share, valuing Aurora at approximately C$561 million; Aurora shareholders are expected to hold approximately 35% of Organigram’s economic interest and 42% of its voting interest.

Read from the first part of this long document
3 source passages
On November 3, 2026, Aurora and Organigram Global Inc. (“Organigram”) announced that they entered into an arrangement agreement dated November 2, 2026 (the “Arrangement Agreement”) pursuant to which Organigram agreed to acquire all of the issued and outstanding common shares of Aurora (“Aurora Shares”) pursuant to a court-approved plan of arrangement under the Business Corporations Act (British Columbia) (the “Arrangement”). holders of Aurora Shares (“Aurora Shareholders”) (other than dissenting Aurora Shareholders) will receive C$7.80 in total consideration per Aurora Share The Arrangement values Aurora at approximately C$561 million on a fully diluted equity value basis. Aurora Shareholders are expected to hold approximately 35% of the economic interest and 42% of the voting interest in Organigram, on a fully diluted basis, following the completion of the Arrangement. Open the document at this passage
Nov 3
Current report 6-K
Acquisition agreed at C$7.80 per share with 93% premium

Aurora Cannabis Inc. agreed to sell all outstanding shares to Organigram for C$7.80 per share, valuing the company at approximately C$561 million on a fully diluted basis and representing a 93% premium; completion is expected in January 2027.

3 source passages
Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI) (“Organigram”) and Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) (“Aurora”) today announced that they have entered into an arrangement agreement (the “Arrangement Agreement”) pursuant to which Organigram will acquire all of the issued and outstanding common shares (the “Aurora Shares”) of Aurora at a price of C$7.80 per Aurora Common Share (the “Transaction”). The Transaction values Aurora at approximately C$561 million on a fully diluted equity value basis. The consideration represents a 93% premium to the unaffected closing share price of Aurora Shares on the TSX as of August 10, 2026, the last full trading day of Aurora prior to the announcement by Curaleaf Holdings, Inc. (“Curaleaf”) of its intention to launch a hostile takeover bid for Aurora (the “Unaffected Price”), and a 21% premium relative to the current bid value of the Curaleaf hostile offer^3^ (the “Hostile Bid”) as most recently amended on October 6, 2026, which was unanimously rejected by Aurora’s Board of Directors. Subject to the satisfaction of such conditions, the Transaction is expected to be completed in January 2027. Open the document at this passage
Oct 29
Current report 6-K
Current report

Aurora Cannabis will discuss second quarter 2027 financial results on Thursday, November 12, 2026 at 8:00 a.m. Eastern Time and 6:00 a.m. Mountain Time. Miguel Martin and Simona King will host the call.

Oct 26
Current report 6-K
Current report

The Alberta Securities Commission dismissed Curaleaf’s application to halt Aurora’s ATM program, which Aurora said complies with securities laws. Aurora last used the ATM on August 18, 2026 and unanimously urged shareholders to reject Curaleaf’s revised hostile bid.

Oct 14
Current report 6-K
Current report

Aurora Cannabis Inc. recommends shareholders reject Curaleaf Holdings, Inc.’s revised hostile bid, take no action before December 4, 2026, and await its Special Committee’s evaluation of strategic alternatives.

Oct 8
Current report 6-K
Current report

Aurora Cannabis Inc. completed expansion of its Leuna, Germany EU-GMP facility, renamed Aurora Horizon, increasing cultivation capacity and more than doubling expected annual flower output; newly built areas received an expanded EU-GMP license.

Oct 7
Current report 6-K
Current report

Aurora Cannabis Inc urged shareholders to take no action on Curaleaf’s revised hostile bid, which offers US$5.00 per share, while its Special Committee reviews it; shareholders have until at least December 4, 2026 to consider their options.

Oct 6
Current report 6-K
Current report

Aurora Cannabis Inc advised shareholders to take no action pending its Special Committee’s review because Curaleaf has not filed a formal revised hostile bid; shareholders have until December 4, 2026, with a Board recommendation expected within 15 days.

Sep 24
Current report 6-K
Current report

Aurora Cannabis Inc. asked the Alberta Securities Commission to require Curaleaf to correct hostile bid disclosure deficiencies including pro forma financials and the required 105-day deposit period. The Board unanimously recommends shareholders reject take no action and not tender shares.

Showing 1–50 of 1,201 documents